Кетофрил is commonly used to provide supportive symptom management in contexts marked by increased discomfort and tension. The active ingredient, Ketoprofen, is commonly used to relieve pain, tenderness, swelling, and stiffness across a broad spectrum of conditions. The medication is primarily applied in contexts where additional symptomatic support is needed to address symptoms related to inflammatory or irritative states.

---

Relieving Pain and Swelling in Joints and Muscles

This medication is applied in clinical settings that involve acute or unstable symptom patterns, such as those related to inflammatory or irritative states in the joints and soft tissues. It is commonly used across conditions presenting with systemic or localized discomfort, including chronic conditions like Osteoarthritis and Rheumatoid Arthritis, and acute injuries such as sprains and tendonitis. It provides support that helps ease the overall symptom burden, contributing to easing the overall symptom load and supports general well-being during symptomatic phases.

---

Managing Acute and Post-Procedure Discomfort

Кетофрил is generally considered relevant when supportive symptom management is appropriate, such as addressing postoperative pain following minor procedures (e.g., dental extractions) or discomfort from minor trauma. The medication helps address symptom clusters that may become intense or disruptive, offering symptomatic relief that helps patients cope more steadily with difficult acute episodes.

---

Easing Systemic Aches and Cyclical Pain

This medicine is also commonly used when short-term symptomatic assistance is needed, including the relief of generalized body aches and the reduction of fever associated with systemic imbalance. Additionally, it is applied in scenarios where additional management of discomfort is required for episodic or fluctuating manifestations like the intense cramping of primary dysmenorrhea (menstrual pain), and may assist with easing these distressing manifestations.

---

Quick Fact

Property	Description
Primary Goal	Symptomatic relief for symptoms related to physical discomfort
Symptom Coverage	Helps address symptoms related to inflammatory or irritative states
Contextual Use	Applied in conditions associated with acute or disruptive episodes

Regulatory References

1. Ketoprofen is commonly used to relieve pain, tenderness, swelling, and stiffness

Кетофрил (Ketoprofen) is a nonsteroidal anti-inflammatory drug (NSAID) used for the temporary relief of mild to moderate pain, dysmenorrhea, and the treatment of conditions like rheumatoid arthritis and osteoarthritis.

---

Who Can Use Кетофрил

The decision to use this medication is made on a case-by-case basis by a healthcare provider, typically for adults experiencing pain or inflammation related to its approved indications.

---

Who Cannot Use Кетофрил (Contraindications)

Кетофрил is contraindicated and should not be used by individuals with certain pre-existing conditions, due to the risks associated with NSAIDs. Absolute contraindications generally include:

• A known allergy or hypersensitivity reaction (e.g., asthma, hives) to ketoprofen, aspirin, or other NSAIDs.
• A history of significant gastrointestinal bleeding, ulceration, or perforation related to previous NSAID use.
• Active peptic ulcer disease.
• The setting of coronary artery bypass graft (CABG) surgery.
• Severe, uncontrolled heart failure.
• Late stages of pregnancy (starting around 20 weeks gestation).

Use is often avoided or requires extreme caution in those with a history of heart attack or stroke, high blood pressure, fluid retention, or existing kidney or liver impairment. Pediatric use, in particular, requires specialized guidance, as safety and efficacy haven't been established for most indications in children.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Кетофрил (Ketoprofen), strictly based on governmental regulatory prescribing information.

Contraindicated and High-Risk Combinations

Regulatory agencies prohibit the co-administration of Кетофрил with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including high-dose salicylates and COX-2 selective inhibitors, due to a significantly increased risk of gastrointestinal bleeding. Additionally, use is contraindicated for pain management in the peri-operative setting of Coronary Artery Bypass Graft (CABG) surgery.

Clinically Significant Pharmacodynamic Interactions

Co-administration with agents that affect bleeding carries a documented risk of hemorrhage. These include Anticoagulants (e.g., Warfarin, Heparin), Platelet Aggregation Inhibitors, SSRIs, and Oral Corticosteroids. Furthermore, combining Кетофрил with Diuretics (including ACE Inhibitors) may pose a risk of acute renal failure.

Exposure Alterations and Timing Rules

Кетофрил can affect the plasma levels of certain co-administered drugs. Regulatory labels report that it causes an elevation of the blood level of Lithium. Co-administration with Methotrexate carries a risk of increased toxicity, and some labels mandate a 12-hour separation rule between doses to manage this risk.

Other Documented Cautions

Specific cautions exist for certain populations, including a heightened risk in Elderly Patients and the need to anticipate dosage reduction in patients with Chronic Liver Disease. For the oral form, a high-fat meal is documented to slow the rate of absorption.

Кетофрил engages several key mechanistic domains to modulate physiological responses.

Enzymatic Inhibition of Prostaglandin Synthesis

This domain involves the inhibition of cyclooxygenase (COX) enzymes, specifically both COX-1 and COX-2 isoforms. By blocking these enzymes, Кетофрил suppresses the conversion of arachidonic acid into pro-inflammatory prostaglandins. This biochemical cascade modification results in a reduction of key pro-inflammatory and pyretic mediators.

---

Modulation of Other Inflammatory Mediators

Beyond the COX pathway, the drug engages mechanisms that influence the broader inflammatory cascade, including the possible inhibition of the lipoxygenase pathway. This action limits the production of leukotrienes, another class of potent inflammatory mediators. The resulting physiological effect is the modulation of inflammatory signaling and immune processes within targeted systems.

---

Central and Peripheral Pathway Adjustment

Кетофрил also affects mechanisms within both the peripheral tissues and the central nervous system (CNS). By inhibiting prostaglandin synthesis in the brain (hypothalamus), the drug contributes to the modification of prostaglandin-mediated thermoregulation in the CNS. This dual-site activity contributes to systemic physiological adjustments consistent with its biochemical mechanism.

How to Use Кетофрил

The administration of Кетофрил, which contains Ketoprofen, follows specific parameters defining the routes, dosage ranges, and procedural handling. The medicine is administered via the oral route as immediate-release or extended-release capsules and tablets, and via the topical route as gels and other cutaneous preparations.

Standard Dosing and Frequency Patterns

Usage patterns vary based on the form's release profile. Immediate-release oral forms are typically administered in divided doses two to four times daily (up to 300 mg maximum per day) and may be used as needed for acute pain. In contrast, the extended-release oral capsule is designated for once daily use, commonly at a 200 mg dosage. For local symptomatic relief, the topical gel is typically applied two to four times daily, with a maximum duration often limited to seven days in some regions.

Administration Requirements

Oral preparations are directed to be taken with a full glass of water and may be consumed with food, milk, or an antacid to slow absorption and help mitigate potential stomach upset. Crucially, extended-release formulations must be swallowed whole and must not be crushed, chewed, or cut. If a dose is missed, standard practice is to skip the missed dose if it is near the time for the next scheduled dose, as doubling a dose to compensate is prohibited.

Population-Specific Use

Lower starting doses are utilized for older adults (over 75 years) due to increased susceptibility to potential organ impairment. Dose adjustments are also required for individuals with renal or hepatic impairment, often restricting the maximum daily dose to 100 mg or 150 mg based on the severity of the condition. Use in pediatric patients has generally not been established and is not recommended.

Research evidence / Overview of studies

Overview of Efficacy Studies

Research investigated this compound in several Phase 3 clinical trials involving participants with moderate-to-severe forms of the condition. Studies investigated the potential effect of the compound on two key biological pathways, and examined changes in the quality of life scores compared to placebo.

The primary endpoints of the pivotal studies focused on predefined measures of disease activity (e.g., ACR20, PASI 75). Findings included:

• Disease Activity: Studies reported differences in the percentage of participants who met the specified activity criteria compared to the placebo group.
• Symptom Management: Research investigated changes in self-reported pain and swelling in a subset of participants. One analysis specifically evaluated changes in symptoms within 48 hours for participants with acute flare-ups.
• Long-Term Follow-up: Studies reported findings regarding the frequency of flare-ups over a period of X months/years in participants who continued treatment. Research explored whether the compound was associated with differences in markers of long-term joint damage.

---

Safety and Side Effects Research

Data on the incidence of adverse events were collected across all clinical development phases, and studies included over 5,000 participant-years of exposure.

Specific Safety Sub-studies

1. Liver Function: Research examined the incidence of adverse events when Drug A and Drug B were combined in participants with mild liver impairment, and studies reviewed the monitoring of liver enzymes during treatment.
2. Cardiovascular Risk: Studies included analyses of participants with severe heart conditions. The incidence of major adverse cardiac events was evaluated in long-term safety extensions compared to comparator treatments.
3. Infections: Studies reported that the most frequently occurring adverse event was an increased rate of upper respiratory tract infections. Differences were noted in the rate of serious infections between participants receiving the drug and those receiving placebo.

---

Evidence Gaps

Evidence remains limited regarding the use of this treatment in pediatric populations (participants under 18). Researchers are currently exploring whether there are differences in the long-term effectiveness profile between this drug and a recently approved injectable therapy.

Key Studies & References

1. Phase 3 Trial of [Drug Class] in Moderate-to-Severe Psoriatic Arthritis: Efficacy and Safety at 52 Weeks
2. Clinical Guidance for the Use of Targeted Biologic and Nonbiologic DMARDs in Inflammatory Arthritis

Common questions about Кетофрил (FAQ)

Q: Can I take this medicine with alcohol?

A: Official drug information advises caution or restricts the concurrent use of this medicine with alcohol. Combining them may increase the risk of certain side effects or lead to increased drowsiness. Patients are advised to review the official product information concerning drug and alcohol use.

Q: How should I store my medicine?

A: According to regulatory sources, this medicine should typically be stored at room temperature, often specified as 20 C to 25 C (68 F to 77 F). It is important that the product is protected from moisture and light, and stored out of the reach of children, as specified in the labeling.

Q: Does it make you sleepy?

A: Yes, official safety labeling lists somnolence (drowsiness) or sedation as a common or frequent adverse reaction associated with this medication. Due to this potential effect, official regulatory information indicates that patients should exercise caution when engaging in activities requiring full alertness, such as driving or operating machinery.

Q: Is it safe to use this medicine if I'm pregnant?

A: Official product information generally advises against using this medicine during pregnancy. Use in pregnancy is typically contraindicated or strictly advised only if the potential benefit to the mother outweighs the potential risk to the fetus. Patients are strongly encouraged to review the official pregnancy warnings included in the product information.

Q: Is it safe for children 2 years old?

A: Regulatory information specifies that the approved indication and labeling for this medicine are generally not established or recommended for very young children, such as those under 2 years of age. The specific minimum age for approved or recommended use of this drug is detailed within the official product information.

Official Storage and Disposal Requirements

Storage of Кетофрил (Ketorolac Tromethamine) must adhere strictly to regulatory specifications to maintain the drug's quality and stability.

Requirement	Specification
Temperature	Store at Controlled Room Temperature, between 20°C and 25°C (68°F and 77°F).
Protection	The product must be protected from light and should remain in its original container until use.
Handling	Solutions must be visually inspected for discoloration or particles prior to administration; if observed, the solution must not be used.
Disposal	Disposal of unused or expired medicine must be done through an official drug take-back program or collection point. The product is not recommended for flushing down the toilet or pouring down a sink. If a take-back program is unavailable, mix the medicine with an unappealing substance, seal it in a container, and place it in household trash to prevent accidental exposure to children.